Back pain: Ccn2a protein reversed Intervertebral disc (IVD) degeneration in animal model

In a recent in-vivo study on Zebrafish, researchers successfully induced disc regeneration in a degenerated disc by activating an endogenous Ccn2a-FGFR1-SHH signalling cascade. This suggests that Ccn2a protein could be exploited in promotion of IVD regeneration for treatment of backpain.  

Back pain is a common health problem. It is one of the most common reasons for people to seek appointment with doctors. The condition is mainly due to degeneration of intervertebral disc (IVD) which occurs naturally due to wear and tear or ageing. Analgesics and anti-inflammatories along with physiotherapy are currently used to treat the symptoms. In severe cases, disc replacement or disc fusion surgery may be resorted. As such, there is no cure. No known medical treatment or procedure is helpful in restoring disc homeostasis. The solution to the problem lies in finding a way to supress the disc degeneration and/or to induce disc regeneration.  

In an in-vivo study on Zebrafish, reported on 6th January 2023, the researchers discovered that Cellular communication network factor 2a (Ccn2a), a protein secreted by the cells of the intervertebral disc induces disc regeneration in old degenerated discs by promoting cell proliferation and cell survival by modulation of the FGFR1-SHH (Fibroblast growth factor receptor-Sonic Hedgehog) pathway.  

Apparently, this is for the first time that disc regeneration in a degenerated disc has been induced in vivo by activating an endogenous signalling cascade.  

This development may be a steppingstone towards designing a novel strategy to suppress disc degeneration or induce disc regeneration in degenerated human discs.  

*** 

References:  

Rayrikar A.Y., et al 2023. Ccn2a-FGFR1-SHH signaling is necessary for intervertebral disc homeostasis and regeneration in adult zebrafish. Development. Volume 150, Issue 1. Published 06 January 2023. DOI: https://doi.org/10.1242/dev.201036 

*** 

Latest

Brain-Computer Interfaces (BCI): Towards Humans’ Merger with AI 

The ongoing clinical trials of Brain-Computer Interfaces (BCIs) such...

Tumour Treating Fields (TTFields) approved for Pancreatic cancer

Cancer cells have electrically charged parts hence are influenced...

Scientific European invites Co-founder

Scientific European (SCIEU) invites you to join as a Co-Founder and investor, with both...

Future Circular Collider (FCC): CERN Council reviews Feasibility Study

The quest for the answers to the open questions (such as, which...

Chernobyl Fungi as Shield Against Cosmic Rays for Deep-Space Missions 

In 1986, the 4th unit of Chernobyl Nuclear Power Plant in Ukraine...

Myopia Control in Children: Essilor Stellest Eyeglass Lenses Authorised  

Myopia (or near-sightedness) in children is a highly prevalent...

Newsletter

Don't miss

Rejuvenation of Old Cells: Making ageing Easier

A groundbreaking study has discovered a novel way to...

NLRP3 Inflammasome: A Novel Drug Target for Treating Severely Ill COVID-19 Patients

Several studies indicate that activation of NLRP3 inflammasome is...

A New Drug to Fight Advanced Drug-resistant HIV Infection

Researchers have designed a novel HIV drug ibalizumab which...

Moderate Alcohol Consumption May Decrease Risk of Dementia

A study suggests that both excessive consumption of alcohol...

A Novel Method Which Could Help Forecast Earthquake Aftershocks

A novel artificial intelligence approach could help predict location...

COVID-19: An Evaluation of Herd Immunity and Vaccine Protection

Herd immunity for COVID-19 is said to be achieved...
SCIEU Team
SCIEU Teamhttps://www.scientificeuropean.co.uk
Scientific European® | SCIEU.com | Significant advances in science. Impact on humankind. Inspiring minds.

Brain-Computer Interfaces (BCI): Towards Humans’ Merger with AI 

The ongoing clinical trials of Brain-Computer Interfaces (BCIs) such as Neuralink’s “Telepathy” implant involve establishing communication links between the brains of participants who have unmet medical needs due...

Tumour Treating Fields (TTFields) approved for Pancreatic cancer

Cancer cells have electrically charged parts hence are influenced by electric fields. Application of alternating electric fields (TTFields) to solid tumours selectively target and...

Scientific European invites Co-founder

Scientific European (SCIEU) invites you to join as a Co-Founder and investor, with both strategic investment and active contribution in shaping its future direction.  Scientific European is an England-based media outlet providing multilingual...